Evidence map›Paper›PMID 36930668›Full record

ArticlePloS one2023

Which clinical research questions are the most important? Development and preliminary validation of the Australia & New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network Research Question Importance Tool (ANZMUSC-RQIT).

William J Taylor, Robin Willink, Denise A O'Connor, Vinay Patel, Allison Bourne, Ian A Harris, Samuel L Whittle, Bethan Richards, Ornella Clavisi, Sally Green and 15 more

Full text read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

William J TaylorUniversity of Otago, Wellington, New Zealand.ORCID 0000-0001-6075-8479
Robin WillinkUniversity of Otago, Wellington, New Zealand.ORCID 0000-0002-5447-3626
Denise A O'ConnorDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Victoria, Australia.ORCID 0000-0002-6836-122X
Vinay PatelUniversity of Otago, Wellington, New Zealand.
Allison BourneDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
Ian A HarrisWhitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Liverpool, Australia.ORCID 0000-0003-0887-7627
Samuel L WhittleDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
Bethan RichardsSchool of Clinical Medicine, UNSW Sydney, Liverpool, NSW, Australia.
Ornella ClavisiMusculoskeletal Australia, Melbourne, VIC, Australia.
Sally GreenSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Rana S HinmanCentre for Health, Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, Faculty of Medicine Dentistry & Health Sciences, The University of Melbourne, Melbourne, VIC, Australia.
Chris G MaherSydney School of Public Health, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-1628-7857
Ainslie CahillArthritis Australia, Sydney, NSW, Australia.
Annie McPhersonConsumer Partner, ANZMUSC, Melbourne, Australia.
Charlotte HewsonConsumer Partner, ANZMUSC, Melbourne, Australia.
Suzie E MayConsumer Partner, ANZMUSC, Melbourne, Australia.
Bruce WalkerEmeritus Professor in the College of Science, Health, Engineering and Education (SHEE), Murdoch University, Murdoch, WA, Australia.
Philip C RobinsonUniversity of Queensland School of Medicine, Brisbane, QLD, Australia.
Davina GhersiNational Health and Medical Research Council of Australia, Canberra, ACT, Australia.
Jane FitzpatrickUniversity of Melbourne, Melbourne, VIC, Australia.
Tania WinzenbergMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Kieran FallonANU College of Health and Medicine, Australian National University, Garran, ACT, Australia.
Paul GlasziouInstitute for Evidence-Based Healthcare, Bond University, Gold Coast, Australia.
Laurent BillotThe George Institute for Global Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.ORCID 0000-0002-4975-9793
Rachelle BuchbinderDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsHigh quality clinical research that addresses important questions requires significant resources. In resource-constrained environments, projects will therefore need to be prioritized. The Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network aimed to develop a stakeholder-based, transparent, easily implementable tool that provides a score for the 'importance' of a research question which could be used to rank research projects in order of importance.

methodsUsing a mixed-methods, multi-stage approach that included a Delphi survey, consensus workshop, inter-rater reliability testing, validity testing and calibration using a discrete-choice methodology, the Research Question Importance Tool (ANZMUSC-RQIT) was developed. The tool incorporated broad stakeholder opinion, including consumers, at each stage and is designed for scoring by committee consensus.

resultsThe ANZMUSC-RQIT tool consists of 5 dimensions (compared to 6 dimensions for an earlier version of RQIT): (1) extent of stakeholder consensus, (2) social burden of health condition, (3) patient burden of health condition, (4) anticipated effectiveness of proposed intervention, and (5) extent to which health equity is addressed by the research. Each dimension is assessed by defining ordered levels of a relevant attribute and by assigning a score to each level. The scores for the dimensions are then summed to obtain an overall ANZMUSC-RQIT score, which represents the importance of the research question. The result is a score on an interval scale with an arbitrary unit, ranging from 0 (minimal importance) to 1000. The ANZMUSC-RQIT dimensions can be reliably ordered by committee consensus (ICC 0.73-0.93) and the overall score is positively associated with citation count (standardised regression coefficient 0.33, p<0.001) and journal impact factor group (OR 6.78, 95% CI 3.17 to 14.50 for 3rd tertile compared to 1st tertile of ANZMUSC-RQIT scores) for 200 published musculoskeletal clinical trials.

conclusionWe propose that the ANZMUSC-RQIT is a useful tool for prioritising the importance of a research question.

Indexed as

PublicationsAustraliaConsensusHumansNew ZealandReproducibility of Results

Identifiers

PMID36930668
PMCPMC10022765

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read48
identifiers read12
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.